$1.35
0.10[8.00%]
At close: Apr 30
$1.35
0[0.00%]
After Hours: 4:48PM EDT
Latest News for Veru Stock (NASDAQ:VERU)
Veru Stock (NASDAQ: VERU)
Categories: All
Tuesday, April 30, 2024
Monday, April 15, 2024
- Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day SessionAvi Kapoor - Apr 15, 2024, 2:11PM
- Cisco To Rally Around 24%? Here Are 10 Top Analyst Forecasts For MondayAvi Kapoor - Apr 15, 2024, 8:39AM
- Oppenheimer Reiterates Outperform on Veru, Lowers Price Target to $5Benzinga Newsdesk - Apr 15, 2024, 7:55AM
Friday, April 12, 2024
Tuesday, April 09, 2024
Thursday, March 28, 2024
- Veru shares are trading higher after Raymond James initiated coverage on the stock with an Outperform rating and a price target of $3.Benzinga Newsdesk - Mar 28, 2024, 7:18AM
- Raymond James Initiates Coverage On Veru with Outperform Rating, Announces Price Target of $3Benzinga Newsdesk - Mar 28, 2024, 6:10AM
Wednesday, March 27, 2024
Wednesday, February 28, 2024
Thursday, February 08, 2024
Tuesday, February 06, 2024
Monday, January 08, 2024
Tuesday, December 26, 2023
Thursday, December 14, 2023
Wednesday, December 13, 2023
Monday, December 11, 2023
Wednesday, October 04, 2023
- Stocks That Hit 52-Week Lows On WednesdayBenzinga Insights - Oct 4, 2023, 12:01PM
- Veru To Advance Enobosarm Into A Phase 2b Clinical Trial In Combination With Weight Loss GLP-1 Drugs Ozempic, Wegovy Or Mounjaro To Evaluate Efficacy And Safety Of Enobosarm To Further Increase Fat Loss While Preventing Muscle WastingBill Haddad - Oct 4, 2023, 8:33AM
Monday, October 02, 2023
Friday, September 29, 2023
Wednesday, September 27, 2023
Tuesday, September 26, 2023
- 11 Consumer Staples Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - Sep 26, 2023, 9:06AM
- Veru Reaches Agreement With FDA On New Phase 3 Clinical Trial For Sabizabulin For Broader Indication: Hospitalized Adult Patients With Any Type Of Viral Acute Respiratory Distress SyndromeBenzinga Newsdesk - Sep 26, 2023, 8:34AM
Tuesday, September 19, 2023
Monday, September 11, 2023
Thursday, August 10, 2023
Thursday, July 20, 2023
Wednesday, June 07, 2023
- 6 Analysts Have This to Say About VeruBenzinga Insights - Jun 7, 2023, 3:01PM
- Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2023Benzinga Insights - Jun 7, 2023, 11:00AM
- What 6 Analyst Ratings Have To Say About VeruBenzinga Insights - Jun 7, 2023, 8:09AM
- Jefferies Upgrades Veru to Hold, Announces $1 Price TargetBenzinga Newsdesk - Jun 7, 2023, 5:18AM
Tuesday, May 16, 2023
Monday, May 15, 2023
Thursday, May 11, 2023
- Veru shares are trading lower after the company reported worse-than-expected Q2 EPS results.Benzinga Newsdesk - May 11, 2023, 1:00PM
- Veru Q2: Revenue Halves, Prioritizes Clinical Programs, Wider Loss & MoreNabaparna Bhattacharya - May 11, 2023, 10:58AM
- Earnings Scheduled For May 11, 2023Benzinga Insights - May 11, 2023, 9:58AM
- Veru: Q2 Earnings InsightsBenzinga Insights - May 11, 2023, 6:40AM
- Veru Q2 EPS $(0.48) Misses $(0.33) Estimate, Sales $6.59M Beat $4.32M EstimateBenzinga Newsdesk - May 11, 2023, 6:32AM